Monitoring heart enzyme during immunotherapy
Part of Immune system & allergy clinical trials.
This study is for people starting immunotherapy with checkpoint inhibitors. It checks a heart enzyme (troponin) to see if the treatment affects your heart, so your doctor can monitor and manage any changes early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are about to start treatment with an immune checkpoint inhibitor (a type of immunotherapy) as part of your standard cancer care.
- You are willing to have a blood test for troponin T (a heart enzyme) before starting the immunotherapy.
- You have not had a major heart problem (like a heart attack or heart failure) in the past 30 days.
- You are able to keep all study appointments and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your body responds to immunotherapy and how to manage side effects. It aims to separate the treatment's benefits from its unwanted reactions.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
This study looks at heart health in people who have finished immunotherapy for melanoma. It uses MRI scans to check for any heart problems that may have developed after treatment.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
This study checks whether a sensitive blood test (troponin) during follow-up can predict how acute myocarditis may improve over time. It may help doctors better follow patients after hospitalization and adjust care sooner.
Hear when a new Immune Checkpoint Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.